In addition, in a cohort of patients with obesity and type 2 diabetes, 3 months of GLP-1 RA therapy improved both olfactory test scores and odor-evoked brain activation in the parahippocampus, as well as yielding cognitive benefits [6]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.